Health Tech Capitol | Propeller Health/GSK asthma inhaler collaboration gets FDA clearance
15594
post-template-default,single,single-post,postid-15594,single-format-standard,tribe-no-js,tribe-bar-is-disabled,ajax_fade,page_not_loaded,,qode-child-theme-ver-1.0.0,qode-theme-ver-9.3,wpb-js-composer js-comp-ver-4.12,vc_responsive

Propeller Health/GSK asthma inhaler collaboration gets FDA clearance

07 Nov Propeller Health/GSK asthma inhaler collaboration gets FDA clearance

Posted at 13:42h in Uncategorized by
0 Likes

Propeller Health has received clearance from the U.S. Food and Drug Administration to market its sensor platform along with the GSK (GlaxoSmithKline) Ellipta inhaler.

Propeller’s customized medication sensor was developed with GSK as part of a collaboration between the two companies announced in December 2015. It will record the dates and times a patient with asthma or COPD (chronic obstructive pulmonary disease) uses the device and will send the data to GSK researchers to analyze.

“We hope to gain valuable insights into usage patterns with the ultimate goal of driving improvements in patient care while reducing the complexity and cost of clinical trials,” said Dave Allen, GSK’s head of respiratory research and development.

It is the eighth FDA clearance for use of the Madison company’s technology.

Read more at the Wisconsin State Journal

No Comments

Sorry, the comment form is closed at this time.